I

111TH CONGRESS
1ST SESSION

H. R. 3475

To amend the Public Health Service Act to double the amount of funds authorized to be appropriated to the National Institutes of Health for medical research with the greatest potential for near-term clinical benefit.

IN THE HOUSE OF REPRESENTATIVES

JULY 31, 2009

Mr. FORBES introduced the following bill; which was referred to the Committee on Energy and Commerce

---

A BILL

To amend the Public Health Service Act to double the amount of funds authorized to be appropriated to the National Institutes of Health for medical research with the greatest potential for near-term clinical benefit.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ''Accelerate Cures for Patients Act of 2009''.

SEC. 2. ADDITIONAL NIH FUNDING FOR RESEARCH WITH GREATEST POTENTIAL FOR NEAR-TERM CLINICAL BENEFIT.

Title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is amended by inserting after section 402A the following:

"SEC. 402A–1. ADDITIONAL FUNDING FOR RESEARCH WITH GREATEST POTENTIAL FOR NEAR-TERM CLINICAL BENEFIT.

''In addition to the amount authorized to be appropriated each fiscal year pursuant to section 402A to conduct or support medical research under this title, there is authorized to be appropriated an equal amount for medical research (relating to cancer, cardiovascular disease, diabetes, Alzheimer's disease, Parkinson's disease, or other diseases or conditions) that (as determined by the Secretary) has the greatest potential for near-term clinical benefit in human patients, as indicated by substantial evidence from basic research or by substantial clinical evidence. Such evidence may include but is not limited to—

''(1) evidence of improvement in one or more human patients suffering from illness or injury, as documented in reports by professional medical or scientific associations or in peer-reviewed medical or scientific literature; or

''(2) approval for use in human trials by the Food and Drug Administration.''.

○